Physician profile
John A Bond
NPI 1003943416
$4,070.91
in general payments reported to CMS, 2019-2025
23 companies · $885 in 2025
The $885 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $426 · 2021: $139 · 2022: $224 · 2023: $468 · 2024: $834 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,182 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,182.42 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,169.49 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $718.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $393.97 | 2019-2025 | Breztri, Farxiga |
| Pfizer INC. | $348.48 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.19 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $250.98 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $190.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Intuitive Surgical, INC. | $129.29 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $102.88 | 2019-2025 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $83.96 | 2019 | |
| Astellas Pharma US INC | $58.19 | 2024-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.45 | 2019-2025 | Xifaxan |
| Inspire Medical Systems, INC. | $42.43 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $42.37 | 2025 | Rexulti |
| Amgen INC. | $35.58 | 2023-2025 | Repatha, Otezla, Otezla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $34.58 | 2023 | |
| Idorsia Pharmaceuticals US INC | $29.64 | 2022-2023 | Quviviq |
| Abbott Laboratories | $22.12 | 2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $19.21 | 2022 | |
| Kerecis Limited | $17.49 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Therapeuticsmd, INC. | $15.30 | 2019 | |
| Tactile Systems Technology INC | $15.15 | 2019 | |
| Merck Sharp & Dohme LLC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.